PIRS - Pieris Pharmaceuticals Inc Stock Price, Fair Value and News

10.91USD-0.33 (-2.94%)Delayed as of 03 May 2024, 12:55 pm ET

Market Summary

USD10.91-0.33

Delayedas of 03 May 2024, 12:55 pm

-2.94%

PIRS Stock Price

View Fullscreen

PIRS RSI Chart

PIRS Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-45.31

Price/Sales (Trailing)

25.94

EV/EBITDA

-48.35

Price/Free Cashflow

-20.6

PIRS Price/Sales (Trailing)

PIRS Profitability

EBT Margin

-57.26%

Return on Equity

-91.72%

Return on Assets

-63.45%

Free Cashflow Yield

-4.86%

PIRS Fundamentals

PIRS Revenue

Revenue (TTM)

42.9M

Rev. Growth (Yr)

-78.75%

Rev. Growth (Qtr)

-93.61%

PIRS Earnings

Earnings (TTM)

-24.5M

Earnings Growth (Yr)

43.42%

Earnings Growth (Qtr)

57.37%

Breaking Down PIRS Revenue

52 Week Range

11.20

(Low)(High)

Last 7 days

-1.9%

Last 30 days

-20.1%

Last 90 days

-21.8%

Trailing 12 Months

-82.6%

How does PIRS drawdown profile look like?

PIRS Financial Health

Current Ratio

3.24

PIRS Investor Care

Shares Dilution (1Y)

9549.95%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.7M	33.3M	47.5M	42.9M
2022	27.0M	27.1M	28.5M	25.9M
2021	31.7M	23.7M	24.9M	31.4M
2020	51.0M	56.9M	44.7M	29.3M
2019	33.5M	27.1M	33.9M	46.3M
2018	28.1M	37.9M	42.3M	29.1M
2017	5.9M	6.7M	9.8M	25.3M
2016	4.0M	4.9M	5.2M	5.8M
2015	4.2M	3.7M	4.1M	2.9M
2014	10.7M	8.9M	7.1M	5.4M
2013	0	0	11.9M	12.4M
2012	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pieris Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 25, 2023	kiritsy christopher p	bought	8,500	0.85	10,000	-
May 13, 2022	demuth tim	bought	10,260	1.71	6,000	chief medical officer
Aug 30, 2021	olwill shane	sold	-196,380	5.11406	-38,400	chief development officer
Aug 30, 2021	olwill shane	acquired	58,368	1.52	38,400	chief development officer
Jul 21, 2020	aquilo capital management, llc	sold	-5,605,000	2.95	-1,900,000	-
Sep 06, 2019	bvf partners l p/il	sold	-224,970	4.4994	-50,000	-
Jan 30, 2019	bvf partners l p/il	sold	-	-	-5,000,000	-

Which funds bought or sold PIRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-7,271	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	1.00	65.00	-%
Apr 23, 2024	Summit Trail Advisors, LLC	new	-	25,648	25,648	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	36.00	5,496	-%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-	-	-%
Apr 12, 2024	HUDSON VALLEY INVESTMENT ADVISORS INC /ADV	unchanged	-	163	2,565	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-5,066	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-12.38	-143,446	165,145	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	100	1,501	8,238	-%

Are Funds Buying or Selling PIRS?

Are funds buying PIRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PIRS

No. of Funds

Unveiling Pieris Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	checkpoint capital l.p.	0%	0	SC 13G/A
Feb 14, 2024	aquilo capital management, llc	1.1%	1,126,761	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	9.9%	9,775,849	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	0.0%	0	SC 13G/A
Aug 17, 2023	biotechnology value fund l p	11.1%	11,007,420	SC 13D/A
Jun 12, 2023	checkpoint capital l.p.	6.0%	4,938,486	SC 13G
May 22, 2023	biotechnology value fund l p	11.8%	11,007,420	SC 13D
Feb 14, 2023	aquilo capital management, llc	5.5%	4,134,009	SC 13G/A
Feb 14, 2023	lynx1 capital management lp	7.6%	5,628,585	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	6.0%	4,623,054	SC 13G/A

Recent SEC filings of Pieris Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Pieris Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Pieris Pharmaceuticals Inc News

Latest updates

Pieris Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-93.6%	1,246,500	19,520,000	20,086,000	2,010,000	5,865,000	5,370,000	3,468,000	11,180,000	8,443,000	4,057,000	3,285,000	15,633,000	1,877,000	2,939,000	11,246,000	13,261,000	17,270,000	15,132,000	5,332,000	8,545,000	4,913,500
Operating Expenses	-81.5%	5,800,000	31,327,000	17,992,000	17,447,000	17,365,000	17,538,000	16,028,000	18,445,000	19,442,000	23,069,000	20,046,000	20,692,000	14,288,000	15,938,000	15,901,000	17,117,000	18,600,000	18,046,000	17,562,000	19,228,000	17,561,500
S&GA Expenses	-66.0%	2,327,000	6,839,000	3,664,000	4,023,000	3,985,000	3,949,000	4,081,000	4,379,000	4,085,000	4,132,000	4,246,000	4,130,000	3,670,000	4,116,000	4,568,000	4,359,000	4,484,000	4,835,000	4,189,000	4,932,000	4,563,500
R&D Expenses	-53.6%	4,454,000	9,595,000	14,328,000	13,424,000	13,380,000	13,589,000	11,947,000	14,066,000	15,357,000	18,937,000	15,800,000	16,562,000	10,618,000	11,822,000	11,333,000	12,758,000	14,116,000	13,211,000	13,373,000	14,296,000	12,998,000
EBITDA Margin	21.0%	-0.46	-0.58	-0.83	-1.67	-1.07	-1.41	-1.47	-1.48	-1.29	-1.29	-1.39	-1.04	-1.12	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-164,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-771,000	-2,592,000	-11,758,000	-10,348,000	-11,847,000
EBT Margin	18.3%	-0.57	-0.70	-1.00	-1.99	-1.29	-1.61	-1.68	-1.70	-1.46	-1.49	-1.56	-1.17	-1.26	-	-	-	-	-	-	-	-
Net Income	57.4%	-4,584,000	-10,752,000	3,976,000	-13,183,000	-8,102,000	-9,736,000	-10,338,000	-5,101,000	-9,532,000	-16,536,000	-15,498,000	-4,172,000	-14,400,000	-14,283,000	-4,950,000	-3,597,000	-771,000	-2,592,000	-11,758,000	-10,348,000	-11,683,000
Net Income Margin	3.1%	-0.57	-0.59	-0.81	-2.47	-1.29	-1.22	-1.53	-1.73	-1.46	-2.04	-2.04	-1.19	-1.27	-	-	-	-	-	-	-	-
Free Cashflow	-100.7%	-19,656,000	-9,792,000	-13,498,000	-11,044,000	-12,922,000	-8,812,000	-16,207,000	-23,032,000	-11,286,000	-14,834,000	29,677,000	-12,166,000	-13,995,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-34.9%	39.00	59.00	88.00	82.00	95.00	99.00	114	137	154	164	155	116	105	116	118	124	141	117	131	131	141
Current Assets	-34.5%	39.00	59.00	66.00	61.00	73.00	79.00	91.00	112	128	138	128	88.00	76.00	89.00	92.00	98.00	115	98.00	111	124	135
Cash Equivalents	-47.1%	17.00	33.00	45.00	40.00	39.00	48.00	54.00	84.00	118	125	119	67.00	70.00	67.00	44.00	47.00	62.00	46.00	55.00	52.00	75.00
Net PPE	-	-	-	16.00	17.00	17.00	16.00	17.00	19.00	19.00	20.00	20.00	21.00	22.00	21.00	21.00	20.00	20.00	11.00	8.00	5.00	5.00
Liabilities	-58.7%	12.00	29.00	47.00	67.00	68.00	63.00	70.00	84.00	103	110	108	78.00	74.00	72.00	71.00	74.00	90.00	96.00	111	101	101
Current Liabilities	-58.7%	12.00	29.00	34.00	43.00	37.00	34.00	36.00	39.00	51.00	50.00	44.00	30.00	22.00	20.00	18.00	20.00	27.00	40.00	41.00	41.00	48.00
Shareholder's Equity	-12.3%	27.00	31.00	40.00	15.00	28.00	1.00	44.00	53.00	51.00	54.00	47.00	38.00	31.00	44.00	47.00	50.00	51.00	21.00	19.00	30.00	40.00
Retained Earnings	-1.5%	-314	-310	-299	-303	-290	-282	-272	-262	-257	-247	-231	-215	-211	-197	-182	-177	-174	-173	-170	-159	-148
Additional Paid-In Capital	0.1%	342	341	340	319	319	317	316	315	307	303	277	254	243	241	230	229	227	195	193	191	190
Shares Outstanding	-100.0%	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	11.00	-	-	-	114	-	-	-	171	-	-	-	117	-	-	-	206	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-102.3%	-19,669	-9,723	-13,431	-10,996	-12,933	-8,778	-15,578	-22,643	-10,944	-14,484	29,906	-12,138	-13,417	-7,570	-9,778	-15,131	-13,974	-12,652	-10,733	-15,108	-9,058
Share Based Compensation	-53.3%	451	966	1,048	884	949	974	1,301	1,178	1,320	1,370	1,326	1,199	1,174	1,396	1,237	1,283	1,114	1,518	1,452	1,290	1,278
Cashflow From Investing	273.8%	3,449	-1,984	-1,366	11,903	1,107	5,470	-10,865	-16,948	-342	-350	-229	-28.00	14,851	18,351	5,596	414	-1,881	4,123	12,912	-5,316	-5,217
Cashflow From Financing	-	14.00	-	19,781	-	93.00	282	281	6,558	4,901	21,916	22,617	9,693	75.00	9,624	416	-	31,665	221	280	-	7.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PIRS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Customer revenue	$ 38,711	$ 25,469
Collaboration revenue	4,099	433
Total revenue	42,810	25,902
Operating expenses
Research and development	41,801	52,982
General and administrative	16,853	16,394
Asset impairment	13,912	0
Total operating expenses	72,566	69,376
Loss from operations	(29,756)	(43,474)
Other income (expense)
Interest income	1,851	721
Grant income	3,612	8,173
Other (expense) income	(250)	1,303
Net loss	(24,543)	(33,277)
Other comprehensive (loss) income:
Foreign currency translation	208	(1,010)
Unrealized gain (loss) on available-for-sale securities	74	(73)
Comprehensive loss	$ (24,261)	$ (34,360)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.27)	$ (0.45)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	90,064	74,172

PIRS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,396	$ 38,635
Short term investments	8,970	20,534
Accounts receivable	572	5,810
Receivable from public grants	3,141	4,771
Other receivables	2,326	462
Assets held for sale, property and equipment	2,188	0
Prepaid expenses and other current assets	4,087	3,212
Total current assets	38,680	73,424
Property and equipment, net	0	16,992
Operating lease right-of-use assets, non-current	0	3,705
Other non-current assets	0	1,369
Total assets	38,680	95,490
Current liabilities:
Accounts payable	3,372	4,154
Operating lease liabilities, current	0	859
Accrued expenses and other current liabilities	8,550	10,746
Deferred revenues, current portion	0	20,824
Total current liabilities	11,922	36,583
Deferred revenue, net of current portion	0	18,734
Operating lease liabilities, non-current	0	12,244
Total liabilities	11,922	67,561
Commitments and Contingencies
Stockholders’ equity:
Convertible preferred stock, $0.001 par value per share, 10,000,000 shares authorized and 15,617 shares issued and outstanding at December 21, 2023 and 2022	0	0
Common stock, $0.001 par value per share, 300,000,000 shares authorized and 98,935,025 and 74,519,103 shares issued and outstanding at December 21, 2023 and 2022, respectively	98	74
Additional paid-in capital	341,596	318,530
Accumulated other comprehensive income	28	(254)
Accumulated deficit	(314,964)	(290,421)
Total stockholders’ equity	26,758	27,929
Total liabilities and stockholders’ equity	$ 38,680	$ 95,490

About Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

CEO	Mr. Stephen S. Yoder J.D.
WEBSITE	pieris.com
INDUSTRY	Biotechnology
EMPLOYEES	127

Pieris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Pieris Pharmaceuticals Inc? What does PIRS stand for in stocks?

PIRS is the stock ticker symbol of Pieris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pieris Pharmaceuticals Inc (PIRS)?

As of Thu May 02 2024, market cap of Pieris Pharmaceuticals Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers. The fair value of Pieris Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pieris Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PIRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pieris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PIRS is over valued or under valued. Whether Pieris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Pieris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIRS.

What is Pieris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, PIRS's PE ratio (Price to Earnings) is -45.31 and Price to Sales (PS) ratio is 25.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIRS PE ratio will change depending on the future growth rate expectations of investors.